Salarius Pharmaceuticals Inc (NASDAQ: SLRX) remained among the day gainers losers and traded with change of -7.32% on volume of 20533 shares in the last session as compared to average volume of 35132 shares. During last trade its minimum price was $5.02 and it gained highest price of $5.53. SLRX has total market capitalization of $19447900. Its closing value stands at $5.19.
Salarius Pharmaceuticals, Inc. (SLRX) reported recently that Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Nationwide Children’s Hospital (Nationwide Children’s) in Columbus, OH have been added as clinical trial sites in the ongoing Phase 1/2 clinical trial of Seclidemstat for the treatment of Ewing sarcoma. The addition of MSKCC and Nationwide Children’s brings the total number of active clinical trial sites to eight.
“We are excited to now be working with Memorial Sloan Kettering Cancer Center and Nationwide Children’s Hospital to further develop our lead cancer drug candidate Seclidemstat as a potential treatment for Ewing sarcoma,” stated David Arthur, President and Chief Executive Officer of Salarius. “Ewing sarcoma is a rare and devastating pediatric bone and soft-tissue cancer for which there are no targeted treatments presently available. We believe Seclidemstat could have a meaningful impact in Ewing sarcoma as a potential new and less toxic treatment, benefitting patients and their families.”
The short ratio in the company’s stock is documented at 1.02 and the short float is around of 2.42%. The Company has 3.64 million shares outstanding and 2.6 million shares were floated in market. The average true range of the stock is observed at 0.67 and the relative strength index of the stock is recorded at 43.08. The volatility in the previous week has experienced by 6.25% and observed of 10.28% in the previous month. 2.10% ownership is held by institutional investors while insiders hold ownership of 0.50%.